Oak Harvest Investment Services Cuts Stake in Qiagen N.V. $QGEN

Oak Harvest Investment Services lessened its holdings in Qiagen N.V. (NYSE:QGEN) by 2.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,710 shares of the company’s stock after selling 1,703 shares during the period. Oak Harvest Investment Services’ holdings in Qiagen were worth $3,735,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of QGEN. Amalgamated Bank increased its holdings in Qiagen by 1.8% during the 2nd quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock worth $565,000 after purchasing an additional 209 shares during the period. Atria Investments Inc boosted its position in shares of Qiagen by 2.9% during the 2nd quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock worth $369,000 after acquiring an additional 218 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its holdings in shares of Qiagen by 9.4% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 2,566 shares of the company’s stock valued at $123,000 after acquiring an additional 221 shares during the last quarter. Yousif Capital Management LLC increased its holdings in shares of Qiagen by 3.7% in the 2nd quarter. Yousif Capital Management LLC now owns 6,257 shares of the company’s stock valued at $301,000 after acquiring an additional 222 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Qiagen by 4.5% during the second quarter. PNC Financial Services Group Inc. now owns 9,672 shares of the company’s stock worth $465,000 after purchasing an additional 415 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Trading Up 0.3%

Shares of QGEN opened at $44.65 on Friday. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $51.88. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $9.92 billion, a P/E ratio of 26.38, a PEG ratio of 2.48 and a beta of 0.64. The firm’s 50-day moving average is $46.25 and its two-hundred day moving average is $46.51.

Qiagen (NYSE:QGEN) last posted its earnings results on Tuesday, November 4th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.03. The company had revenue of $533.00 million for the quarter, compared to the consensus estimate of $525.68 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.Qiagen’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.57 earnings per share. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Q4 2025 guidance at 0.600-0.600 EPS. On average, research analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

QGEN has been the subject of a number of research reports. UBS Group upped their target price on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Barclays set a $53.00 price objective on Qiagen and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday, October 8th. Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Finally, Cowen reissued a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $49.69.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.